Cytokinetics, Incorporated CYTK
55.14 USD +1.45 (+2.70%)
At closeNov 10, 2026, 4:01 AM EST
55.35 +0.21 +0.38%
Pre-market · Nov 10, 4:01 AM ET
53.58 Day range 55.85
53.55 52-week range 88.31
- YTD
- -13.22%
- 1 year
- -8.34%
News
benzinga.com Cytokinetics Presents New Aficamten Data From ACACIA-HCM And FOREST-HCM At HCMS Scientific Sessions 2026 New Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for AficamtenSOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK)…
benzinga.com Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105 Citigroup analyst Eric Joseph maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $99 to $105.
benzinga.com Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100 Leerink Partners analyst Roanna Ruiz maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $103 to $100.
seekingalpha.com Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript
marketbeat.com Cytokinetics Q3 Earnings Call Highlights Cytokinetics NASDAQ: CYTK reported $44.5 million in third-quarter net revenue from heart drug MYQORZO, up 76% from the prior quarter, as the company prepares regulatory submissions that could expand…
zacks.com Cytokinetics (CYTK) Reports Q3 Loss, Beats Revenue Estimates Cytokinetics (CYTK) came out with a quarterly loss of $1.37 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $1.54 per share a year ago.
benzinga.com Cytokinetics Q3 2026 Earnings Call Transcript Cytokinetics (NASDAQ:CYTK) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Cytokinetics Q3 EPS $(1.37) Beats $(1.44) Estimate, Sales $47.557M Beat $41.879M Estimate Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.44) by 4.86 percent. This is a 11.04 percent increase over losses of $(1.54)…
globenewswire.com Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027…
globenewswire.com Cytokinetics to Participate in November Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following…
benzinga.com HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $140 price target.
benzinga.com Cytokinetics Receives Notice Of Compliance From Health Canada Authorizing Treatment Use Of MYQORZO For Symptomatic Obstructive Hypertrophic Cardiomyopathy Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive…
benzinga.com Here's How Much $1000 Invested In Cytokinetics 15 Years Ago Would Be Worth Today Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 15 years by 2.77% on an annualized basis producing an average annual return of 15.73%. Currently, Cytokinetics has a market…- benzinga.com Cytokinetics Presents Additional Data From Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-Obstructive HCM At HFSA Annual Scientific Meeting 2026 Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCMSOUTH SAN FRANCISCO, Calif., Oct. 12,…
benzinga.com Cytokinetics Q2 2026 Earnings Call: Complete Transcript On Thursday, Cytokinetics (NASDAQ:CYTK) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…